Accéder au contenu
Merck

Implementation of newborn screening for Krabbe disease: population study and cutoff determination.

Clinical biochemistry (2009-03-26)
Joseph J Orsini, Mark A Morrissey, Laura N Slavin, Matthew Wojcik, Chad Biski, Monica Martin, Joan Keutzer, X Kate Zhang, Wei-Lien Chuang, Carole Elbin, Michele Caggana
RÉSUMÉ

The aim of this study was to develop a newborn screening algorithm for Krabbe disease. We measured the galactocerebrosidase activity of 139,074 anonymous newborns, 56 known carriers, and 16 Krabbe patients using a tandem mass spectrometry method. The activities were converted to percentages of daily mean activity (%DMA), and the results from diseased and normal populations were used to establish cutoffs. The absolute activities for the newborns ranged from 0.17 to 355 micromol/L h (N=139,074) and activities for Krabbe-positive controls ranged from 0.08 to 0.48 micromol/L h (N=16, n=91 measurements) while activities for carriers ranged from 0.28 to 2.71 micromol/L h (N=56, n=72 measurements). Cutoffs were set based on results from Krabbe-positive and carrier controls and the newborn population distribution. The algorithm and cutoffs we propose provided 100% detection of all positive controls with 60/100,000 screen positive results predicted. In the course of this study, one anonymous newborn was predicted to have Krabbe disease based on enzyme activity and subsequent DNA analysis.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Avanti
C10 Ceramide (d18:1/10:0), Avanti Research - A Croda Brand 860510P, powder